CSR Activities Related to the Compliance Basic Policy Material CSR Issues Review of Fiscal 2013 Initiatives Activities to be Tackled in Fiscal 2014 Promote compliance-related training in every region. Publicly disclose and/or report to authorities information regarding money paid to medical personnel and  institutions in accordance with the Japan Pharmaceutical Manufacturers Association’s Transparency  Guideline, the “Sunshine Act” and other local laws or guidelines. Establish the Global Anti-Bribery and Anti-Corruption Policy and enhance Anti-Bribery and Anti-Corruption  Policy regionally. Enhance guidelines to prevent bribery and corruption through third parties. Conduct third  party due digligence. Hold the Global Compliance Committee meeting and determine global compliance activities for fiscal 2014  (Global Compliance Initiatives for 2014). Compliance with laws and  regulations Business ethics and fair competition Appropriate lobbying and political donations Compliance with the law is fundamental to how Astellas conducts business. Further, we believe that we must uphold  high ethical standards in our business activities and continually ask ourselves whether our activities are acceptable to  society in light of common social norms and customs. Astellas defines compliance broadly to mean conducting our  business activities with high ethical standards in addition to compliance with the law. This concept of compliance is  the cornerstone of our CSR-based management. We believe that always holding ourselves to high ethical standards, fulfilling our social responsibilities, and creating  a sustainable society will help us earn and maintain the trust of stakeholders and enable us to achieve sustainable  growth as a company. To discuss and decide on global policies, training plans and other matters for 14 projects selected as Global  Compliance Initiatives for 2014 by holding meetings with a global task force comprised of representatives from each  of the Company’s regions in order to accelerate and enhance global compliance initiatives. Astellas Pharma Inc.  _ Annual Report 2014 70 comPlIAncE